Citations

Mayo Clinic

Showing 10 of 108551 citations.

Adolescent Presents With Altered Mental Status and Elevated Anion Gap After Suicide Attempt by Ethylene Glycol Ingestion
Schoen, Jessica C. , Cain, Meghan, Robinson, Jeffrey A. , Schiltz, Brenda , Mannenbach, Mark S.

Pediatric Emergency Care | January 19, 2016 | Volume: 32 | Issue: 10 | Pages: 688-690

10.1097/pec.0000000000000606 | PMID 26785093 Get It

Abstract We report the case of a 16-year-old healthy adolescent male who presented to the local emergency department with altered mental status. En route to a tertiary care facility, he began to decompensate and was found to be markedly acidotic. Further investigation revealed an elevated anion gap, and physical examination showed only abdominal pain and decreased level of consciousness. A broad differential diagnosis was considered at the time of the patient's presentation at the tertiary care center including ingestion of a volatile alcohol, sepsis, and an abdominal catastrophe. Although fomepizole and emergent dialysis were being initiated, laboratory tests confirmed ethylene glycol poisoning. This case demonstrates the importance of early recognition of potential ingestions in patients with altered mental status and supportive laboratory findings.
New and Appropriate Goals for Parkinson Disease Physical Therapy
Ahlskog, J. Eric

JAMA Neurology | January 19, 2016 | Volume: 73 | Issue: 3 | Pages: 269

10.1001/jamaneurol.2015.4449 | PMID 26785221 Get It

A 20 Year Practice Review of Electroconvulsive Therapy for Adolescents
Puffer, Chad C., Wall, Christopher A., Huxsahl, John E., Frye, Mark A.

Journal of Child and Adolescent Psychopharmacology | January 19, 2016 | Volume: 26 | Issue: 7 | Pages: 632-636

10.1089/cap.2015.0139 | PMID 26784386 Get It

Objective: Clinical reviews of practice outcomes of adolescent patients who have received electroconvulsive therapy (ECT) remain relatively rare. This study reports the clinic practice and outcome of adolescents receiving ECT at a tertiary medical center. Methods: From April 1991 through November 2013, 51 adolescents (30 female; mean [SD] age, 16.8 [1.6] years) received ECT. The electronic medical record at the time of the first ECT session was reviewed for the clinical diagnosis, ECT lead placement and general administration, seizure duration, adverse effects, concurrent medications, and clinical outcome. Results: ECT was recommended for primary mood and psychotic disorders or catatonia. Patients received a mean (SD) of 9.3 (3.5) treatments, with initial bitemporal lead placement in 36 patients (71%). Thirty-nine patients (77%) were much or very much improved based on Clinical Global Impressions–Improvement scale at the end of the acute treatment. Prolonged seizure duration (>120 seconds) was relatively common (63%) but appeared to decrease in older patients. Conclusions: This report describes the largest group of adolescents receiving ECT since 1947, and supports ECT as a safe and effective modality for most treatment-recalcitrant psychiatric illness in youth.
Direct Evidence of Acetaminophen Interference with Subcutaneous Glucose Sensing in Humans: A Pilot Study
Basu, Ananda , Veettil, Sona, Dyer, Roy B. , Peyser, Thomas A. , Basu, Rita , Dyer, Roy

Diabetes Technology & Therapeutics | January 19, 2016 | Volume: 18 | Issue: 2_suppl | Pages: No page available

10.1089/dia.2015.0410 | PMID 26784129 Get It

Background: Recent advances in accuracy and reliability of continuous glucose monitoring (CGM) devices have focused renewed interest on the use of such technology for therapeutic dosing of insulin without the need for independent confirmatory blood glucose meter measurements. An important issue that remains is the susceptibility of CGM devices to erroneous readings in the presence of common pharmacologic interferences. We report on a new method of assessing CGM sensor error to pharmacologic interferences using the example of oral administration of acetaminophen. Materials and Methods: We examined the responses of several different Food and Drug Administration–approved and commercially available CGM systems (Dexcom [San Diego, CA] Seven ® Plus™, Medtronic Diabetes [Northridge, CA] Guardian ® , and Dexcom G4 ® Platinum) to oral acetaminophen in 10 healthy volunteers without diabetes. Microdialysis catheters were placed in the abdominal subcutaneous tissue. Blood and microdialysate samples were collected periodically and analyzed for glucose and acetaminophen concentrations before and after oral ingestion of 1 g of acetaminophen. We compared the response of CGM sensors with the measured acetaminophen concentrations in the blood and interstitial fluid. Results: Although plasma glucose concentrations remained constant at approximately 90 mg/dL (approximately 5 m M ) throughout the study, CGM glucose measurements varied between approximately 85 to 400 mg/dL (from approximately 5 to 22 m M ) due to interference from the acetaminophen. The temporal profile of CGM interference followed acetaminophen concentrations measured in interstitial fluid (ISF). Conclusions: This is the first direct measurement of ISF concentrations of putative CGM interferences with simultaneous measurements of CGM performance in the presence of the interferences. The observed interference with glucose measurements in the tested CGM devices coincided temporally with appearance of acetaminophen in the ISF. The method applied here can be used to determine the susceptibility of current and future CGM systems to interference from acetaminophen or other exogenous pharmacologic agents.
Magnetic resonance elastography of frontotemporal dementia
Murphy, Matthew C. , Fattahi, Nikoo , Glaser, Kevin J. , Huston, John , Boeve, Bradley F. , Arani, Arvin , Manduca, Armando , Jones, David T. , Ehman, Richard L.

Journal of Magnetic Resonance Imaging | January 19, 2016 | Volume: 43 | Issue: 2 | Pages: No page available

10.1002/jmri.25155 Get It

PurposeTo investigate the feasibility of utilizing brain stiffness as a potential biomarker for behavioral variant frontotemporal dementia (bvFTD) patients. Magnetic resonance elastography (MRE) is a noninvasive technique for evaluating the mechanical properties of brain tissue in vivo. MRE has demonstrated decreased brain stiffness in patients with Alzheimer's disease.Materials and MethodsWe examined five male subjects with bvFTD and nine cognitively normal age‐matched male controls (NC) with brain 3T MRE. Stiffness was calculated in nine regions of interest (ROIs): whole brain (entire cerebrum excluding cerebellum), frontal lobes, occipital lobes, parietal lobes, temporal lobes, deep gray matter / white matter (GM/WM; insula, deep gray nuclei and white matter tracts), cerebellum, sensorimotor cortex (pre‐ and postcentral gyri), and a composite region labeled FT (frontal and temporal lobes excluding the pre‐ and postcentral gyri).ResultsSignificantly lower stiffness values were observed in the whole brain (P = 0.007), frontal lobe (P = 0.001), and temporal lobes (P = 0.005) of bvFTD patients compared to NC. No significant stiffness differences were observed in any other ROIs of bvFTD patients compared to NC (P > 0.05). These results demonstrate that statistically significant brain softening occurs in the frontal and temporal lobes of bvFTD patients, which corresponds to the expected pathophysiology of bvFTD.ConclusionFuture studies evaluating the feasibility of brain MRE for early disease detection and monitoring disease progression could shed new insights into understanding the mechanisms involved in bvFTD. J. Magn. Reson. Imaging 2016;43:474–478.
American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine
Kattan, Michael W. , Hess, Kenneth R. , Amin, Mahul B. , Lü, Ying , Moons, Karl G.M., Gershenwald, Jeffrey E. , Gimotty, Phyllis A. , Guinney, Justin , Halabi, Susan , Lazar, Alexander J. , Mahar, Alyson , Weiser, Martin R. , Compton, Carolyn C. , Core, members of the AJCC Precision Medicine, Compton, Carolyn, Patel, Tushar P , Sargent, Daniel J. , Core, members of the AJCC Precision Medicine, Mahar, Alyson L , Lazar, Alexander J , Halabi, Susan , Lu, Ying , Kattan, Michael W

CA: A Cancer Journal for Clinicians | January 19, 2016 | Volume: 66 | Issue: 5 | Pages: 370-374

10.3322/caac.21339 | PMID 26784705 Get It

The American Joint Committee on Cancer (AJCC) has increasingly recognized the need for more personalized probabilistic predictions than those delivered by ordinal staging systems, particularly through the use of accurate risk models or calculators. However, judging the quality and acceptability of a risk model is complex. The AJCC Precision Medicine Core conducted a 2‐day meeting to discuss characteristics necessary for a quality risk model in cancer patients. More specifically, the committee established inclusion and exclusion criteria necessary for a risk model to potentially be endorsed by the AJCC. This committee reviewed and discussed relevant literature before creating a checklist unique to this need of AJCC risk model endorsement. The committee identified 13 inclusion and 3 exclusion criteria for AJCC risk model endorsement in cancer. The emphasis centered on performance metrics, implementation clarity, and clinical relevance. The facilitation of personalized probabilistic predictions for cancer patients holds tremendous promise, and these criteria will hopefully greatly accelerate this process. Moreover, these criteria might be useful for a general audience when trying to judge the potential applicability of a published risk model in any clinical domain. CA Cancer J Clin 2016;66:370–374. © 2016 American Cancer Society.
Frailty and Mortality Outcomes in Cognitively Normal Older People: Sex Differences in a Population‐Based Study
Bartley, Mairead M., Geda, Yonas E. , Christianson, Teresa J., Roberts, Rosebud O., Petersen, Ronald C. , Christianson, Teresa J H, Pankratz, V. Shane , Geda, Yonas E

Journal of the American Geriatrics Society | January 19, 2016 | Volume: 64 | Issue: 1 | Pages: 132-137

10.1111/jgs.13821 | PMID 26782862 Get It

Objectives To characterize frailty in cognitively normal older adults at baseline and to investigate the relationship between frailty and mortality. Design Population‐based prospective cohort study: Mayo Clinic Study of Aging. Setting Olmsted County, Minnesota. Participants Cognitively normal older persons aged 70 and older (mean age 78.8 ± 5.2, 50.2% male; N = 2,356). Measurements Frailty was assessed at baseline using a 36‐item Frailty Index. Four frailty subgroups were identified based on the Frailty Index (≤0.10 (fit), 0.11–0.20 (at risk), 0.21–0.30 (frail), >0.30 (frailest)). All participants underwent comprehensive clinical and cognitive assessments. The association between frailty and mortality was assessed using Cox proportional hazards models. Results The median Frailty Index was 0.17 (interquartile range 0.11–0.22). Frailty increased with age and was more common in older men than in older women. Over a median follow‐up of 6.5 years (range 7 days to 8.9 years), 500 of the 2,356 participants died, including 292 men. The frailest participants had the greatest risk of death (hazard ratio ( HR ) = 3.91, 95% confidence interval ( CI ) = 2.69–5.68). The association was stronger in women ( HR = 5.26, 95% CI = 2.88–9.61) than men ( HR = 3.15, 95% CI = 1.98–5.02). Conclusion Baseline frailty was common, especially in older men, and increased with age. Frailty was associated with significantly greater risk of death, particularly in women. These sex differences should be considered when designing a geriatric care plan.
The Role of Dynamic (4D) CT in the Detection of Scapholunate Ligament Injury
Breighner, Ryan , Moran, Steven L. , Berger, Richard A. , Zhao, Kristin D. , Breighner, Ryan E., Kakar, Sanjeev , Leng, Shuai , McCollough, Cynthia H. , Trentadue, Taylor P

Journal of Wrist Surgery | January 18, 2016 | Volume: 05 | Issue: 04 | Pages: 306-310

10.1055/s-0035-1570463 | PMID 27777822 Get It

A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Cynthia, X. , Sánchez, César , Crowder, Robert J., Creekmore, Allison, Guo, Zhanfang , Doyle, Austin, Erlichman, Charles , Gao, Feng , Naughton, Michael J. , Pluard, Timothy , Hoog, Jeremy , Lockhart, A. Craig , Ellis, Matthew J. , Sánchez, César

Clinical Cancer Research | January 18, 2016 | Volume: 22 | Issue: 11 | Pages: 2650-2658

10.1158/1078-0432.ccr-15-2160 | PMID 26783290 Get It

Abstract Purpose: PI3K/AKT pathway activation is an important endocrine resistance mechanism in estrogen receptor–positive (ER+) breast cancer. After promising preclinical modeling of MK-2206, an allosteric pan-AKT inhibitor, with either estrogen deprivation or fulvestrant, we conducted a phase I trial in patients with metastatic ER+HER2− breast cancer to determine the recommended phase II treatment dose (RPTD) of MK-2206 when combined with either anastrozole, fulvestrant, or anastrozole/fulvestrant. Experimental Design: ER+ breast cancer cell lines were exposed in vitro to MK-2206 plus estrogen deprivation with or without fulvestrant and monitored for apoptosis. A standard 3+3 design was employed to first determine the maximum tolerated dose (MTD) of MK-2206 plus anastrozole based on cycle 1 toxicity. Each cycle was 28 days. The RPTD was determined on the basis of toxicities observed at MTD level during the first 3 cycles. Subsequent patients received MK-2206, at the RPTD determined above, plus fulvestrant or anastrozole/fulvestrant to define RPTD for these additional regimens. Results: MK-2206 induced apoptosis in parental ER+ but not in long-term estrogen-deprived cell lines, for which fulvestrant was required for apoptosis induction. Thirty-one patients enrolled. The RPTD was defined as MK-2206 150 mg orally weekly with prednisone prophylaxis for each combination. Grade 3 rash was dose limiting. 42% (95% CI, 23%–63%) patients derived clinical benefit without progression within 6 months. Response was not associated with tumor PIK3CA mutation. Conclusions: MK-2206 plus endocrine treatments were tolerable. MK-2206 in combination with anastrozole is being further evaluated in a phase II neoadjuvant trial for newly diagnosed ER+HER2− breast cancer. Clin Cancer Res; 22(11); 2650–8. ©2016 AACR. See related commentary by Jansen et al., p. 2599
Opinion and Special Articles: “Physician debtor”
Jones, Lyell K. , Scharf, Eugene L, Scharf, Eugene , Jones, Lyell K

Neurology | January 18, 2016 | Volume: 86 | Issue: 3 | Pages: No page available

10.1212/wnl.0000000000002299 | PMID 26783273 Get It